Wall Street brokerages expect Cytosorbents Co. (NASDAQ:CTSO) to post earnings per share (EPS) of ($0.10) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for Cytosorbents’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.07). Cytosorbents reported earnings per share of ($0.02) in the same quarter last year, which would suggest a negative year-over-year growth rate of 400%. The firm is expected to issue its next earnings report on Wednesday, November 3rd.
On average, analysts expect that Cytosorbents will report full-year earnings of ($0.37) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.31). For the next year, analysts forecast that the company will post earnings of ($0.02) per share, with EPS estimates ranging from ($0.54) to $0.67. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Tuesday, August 3rd. The medical research company reported ($0.11) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.08). The firm had revenue of $12.02 million during the quarter, compared to the consensus estimate of $12.29 million. Cytosorbents had a negative net margin of 22.97% and a negative return on equity of 13.33%.
Cytosorbents stock traded down $0.22 during midday trading on Monday, hitting $8.51. 294,860 shares of the company’s stock were exchanged, compared to its average volume of 292,923. The company has a market cap of $369.07 million, a P/E ratio of -37.00 and a beta of 0.30. The stock has a 50-day moving average price of $8.17 and a two-hundred day moving average price of $8.35. Cytosorbents has a 52-week low of $6.99 and a 52-week high of $11.68.
Hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. bought a new position in shares of Cytosorbents during the 1st quarter valued at about $29,000. Advisory Services Network LLC purchased a new stake in Cytosorbents in the second quarter worth approximately $56,000. Envestnet Asset Management Inc. purchased a new position in shares of Cytosorbents during the first quarter worth approximately $96,000. HighTower Advisors LLC bought a new stake in shares of Cytosorbents in the 1st quarter worth approximately $102,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Cytosorbents in the 2nd quarter valued at $98,000. 39.99% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Company Profile
CytoSorbents Corp. engages in the critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio include CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Recommended Story: What is the Nikkei 225 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.